Antiproliferative effects of the arotinoid Ro 40-8757 in human gastrointestinal and pancreatic cancer cell lines: Combinations with 5-fluorouracil and interferon-α

British Journal of Cancer

Volumn 74, Issue 3, 1996, Pages 394-399

  Louvet, C ^a   Djelloul, S ^a   Forgue Lafitte, M E ^a   Mester, J ^a   Zimber, A ^a,b   Gespach, C ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Gastric; Human colonic; Pancreatic cancer cell; Retinoid; Ro 40 8757

Indexed keywords

ALPHA2A INTERFERON; AROTINOID; FLUOROURACIL; GROWTH FACTOR; MOFAROTENE; PROTEIN KINASE C; RETINOBLASTOMA PROTEIN; RETINOIC ACID;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DEPHOSPHORYLATION; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PYRIMIDINE METABOLISM; SIGNAL TRANSDUCTION;

EID: 0030035401     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.371     Document Type: Article

References (46)

1. BLOBE GC, SACHS CW, KHAN WA, FABBRO D, STABEL S, WETSEL WC, OBEID LM, FINE RL AND HANNUN YA. (1993). Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. J. Biol. Chem., 268, 658 664.
2. BOLLAG W, MAJEWSKI S AND JABLONSKA S. (1994). Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia, 8, 1453 1457.
3. BUCHOVICH K, DUFFY LA AND HARLOW E. (1989). The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell, 58, 1097 1105.
4. CAO L, FAHA B, DEMBSKI M, TSAI LH, HARLOW E AND DYSON N. (1992). Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F. Nature, 355, 176 179.
5. CASTAIGNE S, CHOMIENNE C, DANIEL MT, BALLERINI P, BERGER R, FENAUX P AND DEGOS L. (1990). All-trans retinoic acid as a differenciation therapy for acute promyelocytic leukemia. I Clinical results. Blood, 76, 1704 1709.
6. CHASTRE E, EMPEREUR S, DI GIOIA Y, EL MAHDANI N, MAREEL M, VLEMINCKX K, VAN ROY F, BEX V, EMAMI S, SPANDIDOS DA AND GESPACH C. (1993). Neoplastic progression of human and rat intestinal cell lines after transfer of ras and polyoma middle T oncogenes. Gastroenterology, 105, 1776 1789.
7. CHELLAPAH SP, HIEBERT S, MUDRYJ M, HOROWITZ JM AND NEVINS JR. (1991). The E2F transcription factor is a cellular target for the Rb protein. Cell, 65, 1053 1061.
8. CHIRGWIN JM, PRZYBYLA AE, MACDONALD RJ AND RUTTER WJ. (1979). Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18, 5294 5299.
9. CRAVEN RJ, CANCE W AND LIU ET. (1995). The nuclear tyrosine kinase rak associates with the retinoblastoma protein pRb. Cancer Res., 55, 3969-3972.
10. DEGOS L, DOMBRET H, CHOMIENNE C, DANIEL MT, MICLÉA JM, CHASTANG C, CASTAIGNE S AND FENAUX P. (1995). All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood, 85, 2643 2653.
11. DELAGE S, CHASTRE E, EMPEREUR S, WICEK D, VELLISIÈRE D, CAPEAU J, GESPACH C AND CHERQUI G. (1993). Increased protein kinase C α expression in human colonic Caco-2 cells after insertion of human Ha-ras or polyoma virus middle T oncogenes. Cancer Res., 53, 2762 2770.
12. DYSON N. (1994). pRB, p107 and the regulation of the E2F transcription factor. J Cell. Sci., 18, (suppl) 81-87.
13. EISENHAUER E, LIPPMAN S, KAVANAGH J, ARNOLD A AND MASSIMINI G (1994). Combination 13-cis-retinoic acid and interferon α-2a in therapy of solid tumors. Leukemia, 8, 1622 1625.
14. ELIASON JE, KAUFMANN F, TANAKA T AND TSUKAGUSHI T. (1993a). Anti-proliferative effects of the arotinoid Ro 40-8757 on human cancer cell lines in vitro. Br. J. Cancer, 67, 1293 1298.
15. ELIASON JF, INOUE T, KUTOHA A, TEELMANN K, HORII I AND HARTMANN D. (1993b). The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of cyclophosphamide. Int. J. Cancer, 55, 492-497.
16. ELIASON JF, INOUE T, KUTOBA A, HORII I AND HARTMANN D. (1994). The antitumor arotinoid Ro 40-8757 protects hone marrow from the toxic effects of 5-fluorouracil. Int. J. Cancer. 57, 192 194.
17. EWEN ME. (1994). The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev., 13, 45-66.
18. FORGUE-LAFITTE ME, COUDRAY AM, BRÉANT B AND MESTER J. (1989). Proliferation of the human colon carcinoma cell line HT29: autocrine growth and deregulation expression of the c-myc oncogene. Cancer Res., 49, 6566-6571.
19. FORGUE-LAFITTE ME, COUDRAY AM, FAGOT D AND MESTER J. (1992). Effects of Ketoconazole on the proliferation and cell cycle of human cancer cell lines. Cancer Res., 52, 6827-6831.
20. HOJO G. (1977). Establishment of cultured cell lines of human stomach cancer. Origin and their morphological characteristics. Niigala Igakukai Zassi, 91, 737 763.
21. HONG WK, ENDICOTT J, ITRI LM, DOOS W, BATSAKIS JG, BELL R, FOFONOFF S, BYERS R, ATKINSON FN, VAUGHAN C, TOTH BB, KRAMER A, DIMERY IW, SKIPPER S AND STRONG S. (1986). 13-cis retinoic acid in the treatment of oral leukoplakia. N. Eng. J. Med., 315, 1501-1505.
22. HONG WK, LIPPMAN SM, ITRI LM, KARP DD, LEE JS, BYERS RM, SCHANTZ SP, DRAMER A, LOTAN R, PETERS L, DIMERY IW, BROWN BW AND GOEPFERT H. (1992). Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N. Eng. J. Med., 323, 795-801.
23. HONG WK AND ITRI LM. (1994). Retinoids and human cancer, in The Retinoids: Biology. Chemistry and Medicine Sporn MB, Roberts AB and Goodman DS (eds) pp. 597-630. Raven Press: New York.
24. KRAEMER KH, DIGIOVANNA JJ, MOSHELL AN, TARONE RE AND PECK GL. (1988) Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N. Eng. J. Med., 318, 1633-1637.
25. LABOISSE C, AUGERON C, COUTURIER-TURPIN MH, GESPACH C, CHERET AM AND POTET F. (1982). Characterization of a newly established human gastric cancer cell line HGT1 bearing histamin H2 receptors. Cancer Res., 42, 1541-1548.
26. LESUFFLEUR T, KORNOWSKI A, LUCCIONI C, MULERIS M, BARBAT A, BEAUMATIN J, DUSSAULX E, DUTRILLAUX B AND ZWEIBAUM A. (1991a). Adaptation to 5-Fluorouracil of the heterogeneous human tumor cell line HT29 results in the selection of cells committed to differenciation. Int. J. Cancer, 49, 1-10.
27. LESUFFLEUR T, KORNOWSKI A, AUGERON C, DUSSAULX E, BARBAT A, LABOISSE C AND ZWEIBAUM A. (1991b). Increased growth adaptability to 5-Fluorouracil and methotrexate of HT29 sub-populations selected for their commitment to differenciation. Int. J. Cancer, 49, 731-737.
28. LIPPMAN SM, KESSLER JF AND MEYSKENS FL Jr. (1987a). Retinoids as preventative and therapeutic anticancer agents (Part I). Cancer. Treat Rep. 71, 391-405.
29. LIPPMAN SM, KESSLER JF AND MEYSKENS FL Jr. (1987b). Retinoids as preventative and therapeutic anticancer agents (Part II). Cancer Treat. Rep., 71, 493-515.
30. LIPPMAN SM, KAVANAGH JJ, PAREDES-ESPINOZA M, DELGADILLO-MADRUENO F, PAREDES-CASILLAS P, HONG WK, HOLDENER E AND KRAKOFF I. (1992). 13-cis retinoic acid plus interferon alpha-2a; highly active systemic therapy for squamous cell carcinoma of the cervix. J. Natl Cancer Inst., 84, 241-245.
31. LOUVET C, EMPEREUR S, FAGOT D, FORGUE-LAFITTE E, CHASTRE E, ZIMBER A, MESTER J AND GESPACH C. (1994). The arotinoid Ro 40-8757 has antiproliferative effects in drugresistant human colon and breast cancer cell lines in vitro. Cancer Lett., 85, 83-86.
32. MANGELSDORF DJ AND EVANS RM. (1995). The RXR heterodimers and orphan receptors. Cell, 83, 841-850.
33. MEYSKENS FL Jr. (1985). Isotretinoin for the treatment if advanced human cancers. In: Retinoids: New Trends in Research and Therapy, JH Sauraut (ed.) pp. 371-374. Karger, Basel.
34. MÜLLER R. (1995). Transcriptional regulation during the mammalian cell cycle. TIG, 11:173-178.
35. MORIARTY M, AND DUNN J. (1982). Etretinate in the treatment of actinic keratosis. Lancet, 1, 364-365.
36. NAGANO M, CHASTRE E, CHOQUET A, BARA J, GESPACH C AND KELLY PA. (1995). Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am. J. Physiol., 268, (Gastrintest Liver Physiol, 31), G431-G442.
37. NISHIZUKA Y. (1986). Studies and perspectives of protein kinase C. Science, 233, 305-312.
38. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene. 11, 493-504.
39. SKEEL RT. (1995). Biologic and pharmacologic basis of cancer therapy, in Handbook of Cancer Chemotherapy, Skeel RT and Lachand RA (eds) pp. 3-17. 4th ed, Little, Brown: Boston.
40. TANAKA T, MAKITA H, OHNISHI M, MORI H, KUMIKO S AND HARA A. (1995). Inhibition of oral carcinogenesis by the arotinoid mofarotene (Ro 40-8757) in male F344 rats. Carcinogenesis, 16, 1903-1907.
41. TEELMAN K AND BOLLAG W. (1988). Therapeutic effect of the arotinoid Ro 15-0778 on chemically induced rat mammary carcinoma. Eur. J. Cancer Clin. Oncol., 24, 1205-1907.
42. TEELMAN K, TSUKAGUCHI T, KLAUS M AND ELIASON JF. (1993). Comparison of the therapeutic effects of a new arotinoid. Ro 40-8757 and all-trans- and 13-cis- retinoic acids on rat breast cancer. Cancer Res., 53, 2319-2325.
43. TOMA S, MONTEGHIRFO S, TASSO P, NICOLO G, SPADIM N, PALUMBO R AND MOLINA F. (1994). Antiproliferative and synergistic effect of interferon alpha-2a, retinoids and their association in established human cancer cell lines. Cancer Lett., 82, 209-216.
44. UCHIDA T, INAGAKI N, FURUICHI Y AND ELIASON J. (1994). Down-regulation of mitochondrial gene expression by the antitumor arotinoid mofarotene (Ro 40-8757). Int. J. Cancer. 58, 891-897.
45. WADLER S. (1992). Antineoplastic activity of the combination of 5-fluorouracil and interferon: preclinical and clinical results. Semin. Oncol. (suppl. 4), 38-40.
46. ZIMBER A, GESPACH C, CARENCE A, CHEDEVILLE A AND ABITA JP. (1993). The effects of synthetic retinoids on the proliferation and differentiation of human colon cancer and promyelocytic leukemia cells in vitro. Fourth International Congress on Anti-Cancer Chemotherapy, Paris, February 2-5, 1993.